(ACET) Adicet Bio - Ratings and Ratios
Gamma Delta T Cell, CAR-T, CD20, CD70
ACET EPS (Earnings per Share)
ACET Revenue
Description: ACET Adicet Bio October 21, 2025
Adicet Bio, Inc. (NASDAQ: ACET) is a Boston-based, clinical-stage biotech that focuses on allogeneic γδ T-cell therapies engineered with chimeric antigen receptors (CARs) for both autoimmune disorders and oncology indications.
Its lead candidate, ADI-001, is an off-the-shelf γδ CAR-T cell targeting CD20 and is currently enrolled in a Phase I trial that enrolls patients with relapsed/refractory B-cell non-Hodgkin lymphoma as well as select autoimmune diseases. A second pipeline asset, ADI-270, is an “armored” γδ CAR-T designed to attack CD70-positive malignancies, with a renal cell carcinoma cohort now recruiting.
Key quantitative signals (as of the most recent 10-Q) include a cash runway of roughly $45 million, R&D spend of $12 million in the last quarter (≈ 30 % of total operating expenses), and a projected 15-20 % year-over-year increase in the U.S. CAR-T market, driven by growing payer acceptance and FDA approvals of allogeneic platforms.
Sector-level drivers that could amplify Adicet’s upside are the accelerating shift toward off-the-shelf cell therapies-estimated to capture > 30 % of the CAR-T market by 2030-and the broader immunotherapy spend, which has risen at a CAGR of ~ 12 % over the past five years.
Given the early-stage nature of its trials, the primary uncertainties are clinical efficacy signals, manufacturing scalability, and the competitive landscape (e.g., allogeneic programs from Fate Therapeutics and Atara Biotherapeutics). Disconfirming evidence would include a failure to meet primary endpoints in Phase I or a material delay in IND filings.
For a deeper dive into how Adicet’s valuation compares to peers and the implied upside under various clinical outcome scenarios, you may find the analyst notes on ValueRay worth a look.
ACET Stock Overview
| Market Cap in USD | 112m |
| Sub-Industry | Health Care Distributors |
| IPO / Inception | 2018-01-26 |
ACET Stock Ratings
| Growth Rating | -80.0% |
| Fundamental | 41.9% |
| Dividend Rating | 0.18% |
| Return 12m vs S&P 500 | -57.8% |
| Analyst Rating | 4.71 of 5 |
ACET Dividends
Currently no dividends paidACET Growth Ratios
| Growth Correlation 3m | 48.1% |
| Growth Correlation 12m | -45.8% |
| Growth Correlation 5y | -86.9% |
| CAGR 5y | -69.24% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.71 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.80 |
| Sharpe Ratio 12m | -1.72 |
| Alpha | -77.48 |
| Beta | 1.630 |
| Volatility | 79.95% |
| Current Volume | 2431.2k |
| Average Volume 20d | 2187.5k |
| Stop Loss | 0.5 (-21.9%) |
| Signal | -1.09 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-118.6m TTM) > 0 and > 6% of Revenue (6% = 390.4k TTM) |
| FCFTA -0.62 (>2.0%) and ΔFCFTA -27.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1701 % (prev 1632 %; Δ 68.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.60 (>3.0%) and CFO -98.1m > Net Income -118.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.48 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (91.1m) change vs 12m ago 0.50% (target <= -2.0% for YES) |
| Gross Margin 25.12% (prev 43.46%; Δ -18.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 3.01% (prev 4.80%; Δ -1.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -45.4k (EBITDA TTM -118.3m / Interest Expense TTM 2000 ) >= 6 (WARN >= 3) |
Altman Z'' -29.29
| (A) 0.68 = (Total Current Assets 127.7m - Total Current Liabilities 17.1m) / Total Assets 163.0m |
| (B) -3.42 = Retained Earnings (Balance) -557.3m / Total Assets 163.0m |
| warn (B) unusual magnitude: -3.42 — check mapping/units |
| (C) -0.42 = EBIT TTM -90.8m / Avg Total Assets 215.9m |
| (D) -18.83 = Book Value of Equity -557.4m / Total Liabilities 29.6m |
| Total Rating: -29.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.87
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda 0.16 = 2.48 |
| 6. ROIC - WACC (= -62.97)% = -12.50 |
| 7. RoE -68.48% = -2.50 |
| 8. Rev. Trend 36.82% = 2.76 |
| 9. EPS Trend 82.65% = 4.13 |
What is the price of ACET shares?
Over the past week, the price has changed by -14.72%, over one month by -25.03%, over three months by -6.91% and over the past year by -51.91%.
Is Adicet Bio a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACET is around 0.27 USD . This means that ACET is currently overvalued and has a potential downside of -57.81%.
Is ACET a buy, sell or hold?
- Strong Buy: 6
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACET price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.2 | 864.1% |
| Analysts Target Price | 6.2 | 864.1% |
| ValueRay Target Price | 0.3 | -53.1% |
ACET Fundamental Data Overview November 05, 2025
P/S = 9.7185
P/B = 0.5168
P/EG = 0.82
Beta = 1.63
Revenue TTM = 6.51m USD
EBIT TTM = -90.8m USD
EBITDA TTM = -118.3m USD
Long Term Debt = 15.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.95m USD (from shortTermDebt, last quarter)
Debt = 15.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -19.4m USD (from netDebt column, last quarter)
Enterprise Value = 92.5m USD (111.9m + Debt 15.4m - CCE 34.7m)
Interest Coverage Ratio = -45.4k (Ebit TTM -90.8m / Interest Expense TTM 2000 )
FCF Yield = -108.4% (FCF TTM -100.3m / Enterprise Value 92.5m)
FCF Margin = -1541 % (FCF TTM -100.3m / Revenue TTM 6.51m)
Net Margin = -1823 % (Net Income TTM -118.6m / Revenue TTM 6.51m)
Gross Margin = 25.12% ((Revenue TTM 6.51m - Cost of Revenue TTM 4.87m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.57 (Enterprise Value 92.5m / Total Assets 163.0m)
Interest Expense / Debt = 0.01% (Interest Expense 2000 / Debt 15.4m)
Taxrate = -0.0% (0.0 / -31.2m)
NOPAT = -90.8m (EBIT -90.8m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 7.48 (Total Current Assets 127.7m / Total Current Liabilities 17.1m)
Debt / Equity = 0.12 (Debt 15.4m / totalStockholderEquity, last quarter 133.4m)
Debt / EBITDA = 0.16 (negative EBITDA) (Net Debt -19.4m / EBITDA -118.3m)
Debt / FCF = 0.19 (negative FCF - burning cash) (Net Debt -19.4m / FCF TTM -100.3m)
Total Stockholder Equity = 173.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -72.80% (Net Income -118.6m / Total Assets 163.0m)
RoE = -68.48% (Net Income TTM -118.6m / Total Stockholder Equity 173.2m)
RoCE = -48.13% (EBIT -90.8m / Capital Employed (Equity 173.2m + L.T.Debt 15.4m))
RoIC = -52.39% (negative operating profit) (NOPAT -90.8m / Invested Capital 173.2m)
WACC = 10.57% (E(111.9m)/V(127.2m) * Re(12.02%) + D(15.4m)/V(127.2m) * Rd(0.01%) * (1-Tc(-0.0)))
Discount Rate = 12.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 45.48%
Fair Price DCF = unknown (Cash Flow -100.3m)
EPS Correlation: 82.65 | EPS CAGR: 39.89% | SUE: 1.91 | # QB: 1
Revenue Correlation: 36.82 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for ACET Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle